Le Lézard
Classified in: Health, Science and technology
Subjects: TRI, FDA

Glenmark receives acceptance from U.S. FDA on its IND application for GRC 54276 to proceed with a Phase 1/2, first-in-human clinical study of the molecule for the treatment of patients with advanced solid tumors and lymphomas


MUMBAI, India and MAHWAH, N.J., March 16, 2023 /PRNewswire/ -- Glenmark Specialty SA, the subsidiary of Glenmark Pharmaceuticals Ltd., an innovation-driven, global pharmaceuticals company received acceptance from the U.S. Food and Drug Administration (FDA) on its Investigational New Drug (IND) application for GRC 54276 to proceed with a Phase 1/2, first-in-human, clinical study of GRC 54276 for the treatment of patients with advanced solid tumors and lymphomas.

PRNE_Glenmark_Logo

GRC 54276 is an orally available, small molecule hematopoietic progenitor kinase 1 (HPK1) inhibitor developed by Glenmark. HPK1-regulated functions are involved in nearly every step of the cancer-immunity cycle making it an attractive target for immuno-oncology. By inhibiting HPK1, GRC 54276 is designed to potentially enhance the patient's own immune system to fight cancers.

A Phase 1/2 multicenter, open-label study to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of GRC 54276 is currently underway in India. GRC 54276 is being studied as monotherapy or in combination with Anti PD-1 or Anti PDL-1 therapy in adults with advanced solid tumors and lymphomas. To date, 16 patients with various type of advanced cancers have been enrolled in this ongoing study in India, and company plans to expand the study at ex-India research sites in the subsequent months. 

"Now that the FDA has accepted our IND application, we look forward to initiating the ongoing Phase 1/2 study at the US sites. This is an important milestone for Glenmark as we continue to advance our oncology pipeline. We are excited about the prospects of what this new class of immune-oncology medicines may mean for patients in need," said Nikhil Amin (MD), Chief scientific officer and President, innovative Medicine Group, Glenmark Pharmaceuticals Ltd.

About Glenmark Pharmaceuticals Ltd.

Glenmark Pharmaceuticals Ltd. (BSE: 532296),(NSE: GLENMARK) is an innovation?driven, global pharmaceutical company with a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 10 world?class manufacturing facilities spread across 4 continents, and operations in over 80 countries. In Vivo/Scrip 100 positions Glenmark amongst the Top 100 Companies Ranked by R&D and Pharmaceutical Sales, 2021; while Generics Bulletin/In Vivo places it in the Top 50 Generics and Biosimilars Companies Ranked by Sales, 2021. The company has been Great Place To Work® Certifiedtm in India, in 2023. Glenmark has impacted over 2.6 million lives over the last decade through its CSR interventions. For more information, visit www.glenmarkpharma.com. Follow us on LinkedIn (Glenmark Pharmaceuticals) and Instagram (glenmark_pharma).

Logo: https://mma.prnewswire.com/media/451507/PRNE_Glenmark_Logo.jpg

 

SOURCE Glenmark Pharmaceuticals Ltd.


These press releases may also interest you

at 09:48
The global orthopedic device market  size is estimated to grow by USD 13.91 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of almost 4.23%  during the forecast period. ...

at 09:45
It takes the average rare disease patient six years to get the right diagnosis. And even once they have a diagnosis, patients may face additional access challenges....

at 09:35
Pager, Inc., a leading digital healthcare enablement and care advocacy company serving 28 million members in the United States and Latin America, and AXA Partners Mexico (APM) today announced a strategic partnership that provides new capabilities to...

at 09:34
G Medical Innovations Holdings Ltd. (GMVD), a telehealth, medical device, and remote patient monitoring company, announced today a Partnership with Peter N Nielsen to Drive Health and Wellness Innovation. G Medical, a leading provider of innovative...

at 09:34
Ivy Rehab proudly announces its inclusion in Modern Healthcare's Best Places to Work in Healthcare 2024 list. This accolade highlights our commitment to fostering a positive and empowering work environment for our 5,000 team members. Ivy is the only...

at 09:30
Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Atara...



News published on and distributed by: